Abstract: Human cytomegalovirus (CMV) is a significant contributor to morbidity and mortality and codons 255-1028 in UL54 with a limit of detection of 240 IU/ml. With this assay, we tested 17 43 specimens that had previously been tested for UL97 drug resistance and identified 3 with 18 UL54 mutations. One of these patients had no concurrent UL97 mutation, pointing towards the 19 need for an assay that facilitates dual UL97/UL54 testing for complete resistance profiling.
drug therapy for CMV infection is ganciclovir (GCV) or its prodrug valganciclovir (VGCV).

24
GCV or VGCV must be activated by phosphorylation before they act on HCMV. This 25 phosphorylation is carried out by the viral kinase UL97, and activated GCV subsequently 26 inhibits the viral DNA polymerase UL54. Clinically, GCV resistance usually arises first from a 27 UL97 mutation resulting in decreased accumulation of activated drug. Subsequent UL54 28 mutations can confer high levels of GCV resistance and variable degrees of cross resistance to 29 the second-line drugs cidofovir (CDV) and foscarnet (FOS) (2).
30
Our group previously published a rapid PCR-and sequencing-based detection method for 31 UL97 mutations conferring ganciclovir resistance (3). This test, currently used to detect 32 mutations directly from clinical specimens, results in sequence for UL97 codons 440-645. This 33 region covers the known drug resistance mutation sites in UL97. However, because UL54 is the 34 target of all currently marketed anti-CMV drugs, a detection method for UL54 mutations is also 35 needed. Polymerase mutations are more likely to emerge after prolonged GCV treatment and 36 typically add to the level of resistance conferred by UL97 mutations or introduce cross-resistance 37 to CDV or FOS (4).
38
Despite its predicted utility in treatment management, clinical tests for UL54 drug 39 resistance mutations have been slower to develop for a number of reasons. Firstly, the coding 40 sequence of UL54 is almost twice that of UL97. In addition, the baseline sequences are more 41 variable and the number and variety of resistance mutations is greater in UL54 than in UL97.
42
Polymerase genotypic testing therefore requires more extensive sequencing, typically covering 43 codons 300-1000. To meet the clinical need for complete CMV drug resistance profiles, we 44 adapted our previous UL97 sequencing method (3) to develop a single assay that amplifies six 45 regions (2 in UL97 and 4 in UL54) and is performed rapidly in 96-well format with a single (Figure 2 ). Furthermore, the PCR products from the lowest dilution were successfully 103 sequenced. Our laboratory's conversion factor for IU/ml to copies/ml puts the limit of detection 104 of this assay around 1,000 copies/ml or better, similar to the sensitivity of the previous UL97-105 only method (3). The assay was repeated on 2-fold serial dilutions of two patient samples and
106
sequencing was successfully performed on the PCR product from the 780 or 390 copies/ml 107 dilutions for all 6 amplicon regions on both patient samples ( Figure S1 ).
108
UL54 mutations in patient specimens. We evaluated residual samples from patients previously 2-240 IU/ml; 3-2,400 IU/ml; 4-24,000 IU/ml; 5-240,000 IU/ml. Lane 6 is a CMV positive 347 control. Equivalent results were obtained for all UL97 and UL54 ROIs. 
